<DOC>
	<DOCNO>NCT02828358</DOCNO>
	<brief_summary>This pilot trial study side effect azacitidine combination chemotherapy infant acute lymphoblastic leukemia myeloid/lymphoid mixed-lineage leukemia ( MLL ) gene rearrangement . Drugs use chemotherapy , methotrexate , prednisolone , daunorubicin hydrochloride , cytarabine , dexamethasone , vincristine sulfate , pegaspargase , hydrocortisone sodium succinate , azacitidine , cyclophosphamide , mercaptopurine , leucovorin calcium , thioguanine work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Giving one drug may kill cancer cell .</brief_summary>
	<brief_title>Azacitidine Combination Chemotherapy Treating Infants With Acute Lymphoblastic Leukemia MLL Gene Rearrangement</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate tolerability azacitidine addition Interfant-06 standard chemotherapy infant newly diagnose acute lymphoblastic leukemia ( ALL ) MLL gene rearrangement ( MLL-R ) . SECONDARY OBJECTIVES : I . To evaluate biologic activity azacitidine pharmacodynamic assessment global deoxyribonucleic acid ( DNA ) methylation peripheral blood mononuclear cell ( PBMCs ) infant treat azacitidine . TERTIARY OBJECTIVES : I . To determine 5 year event-free survival ( EFS ) infants MLL-R treated azacitidine addition Interfant-06 standard chemotherapy . II . To perform comprehensive genome , exome , methylome , transcriptome analysis pre-treatment leukemia blast , remission PMBCs , refractory relapse leukemia blast correlate outcome context protocol therapy . III . To correlate minimal residual disease ( MRD ) outcome context protocol therapy . IV . To perform pharmacokinetic ( PK ) test azacitidine infant . V. To test expansion infant T lymphocytes stimulation artificial antigen present cell identical use chimeric antigen receptor T-cell ( CART ) -19 production . VI . To collect pharmacodynamic ( PD ) data asparaginase activity follow pegaspargase administration infant . OUTLINE : INDUCTION CHEMOTHERAPY : Patients receive methotrexate intrathecally ( IT ) day 1 29 , prednisolone intravenously ( IV ) nasogastrically ( NG ) three time daily ( TID ) day 1-7 , daunorubicin hydrochloride IV 1-15 minute day 8-9 , cytarabine IV 30 minute day 8-21 IT day 15 , dexamethasone orally ( PO ) , NG , IV TID day 8-28 , vincristine sulfate IV 1 minute day 8 , 15 , 22 29 , pegaspargase IV 1-2 hour intramuscularly ( IM ) day 12 , hydrocortisone sodium succinate IT day 15 29 absence disease progression unacceptable toxicity . Only patient MLL-R continue post-induction chemotherapy . POST-INDUCTION CHEMOTHERAPY : AZACITIDINE BLOCK I : Prior CONSOLIDATION , patient receive azacitidine IV 10-40 minute daily 5 day absence disease progression unacceptable toxicity . CONSOLIDATION : Following completion AZACITIDINE BLOCK I , patient receive cyclophosphamide IV 30-60 minute day 1 29 , mercaptopurine PO NG daily day 1-28 , cytarabine IV subcutaneously ( SC ) daily day 3-6 , 10-13 , 17-20 , 24-27 IT day 10 , methotrexate IT day 24 , hydrocortisone sodium succinate IT day 10 24 absence disease progression unacceptable toxicity . AZACITIDINE BLOCK II : Prior INTERIM MAINTENANCE , patient receive azacitidine AZACITIDINE BLOCK I INTERIM MAINTENANCE : Following completion AZACITIDINE BLOCK II , patient receive mercaptopurine PO NG daily day 1-14 , methotrexate IV 24 hour day 1 8 IT day 2 9 , hydrocortisone sodium succinate IT day 2 9 , leucovorin calcium PO IV day 2-3 9-10 , cytarabine IV 3 hour every 12 hour day 15-16 22-23 total 8 dos , pegaspargase IV 1-2 hour IM day 23 absence disease progression unacceptable toxicity . AZACITIDINE BLOCK III : Prior DELAYED INTENSIFICATION PART I , patient receive azacitidine AZACITIDINE BLOCK I . DELAYED INTENSIFICATION PART I : Following completion AZACITIDINE BLOCK III , patient receive pegaspargase IV 1-2 hour IM day 1 , dexamethasone PO , NG , IV TID day 1-14 15-21 taper day 15-21 , thioguanine PO NG daily day 1-28 , vincristine sulfate IV 1 minute day 1 , 8 , 15 , 22 , daunorubicin hydrochloride IV 1-15 minute day 1 , 8 , 15 , 22 , cytarabine IV SC day 2-5 , 9-12 , 16-19 , 23-26 IT day 1-15 , hydrocortisone sodium succinate IT day 1 15 absence disease progression unacceptable toxicity . AZACITIDINE BLOCK IV : Prior DELAYED INTENSIFICATION PART II , patient receive azacitidine AZACITIDINE BLOCK I . DELAYED INTENSIFICATION PART II : Following completion AZACITIDINE BLOCK IV , patient receive thioguanine PO NG daily day 1-14 , cyclophosphamide IV 15-30 minute day 1 15 , cytarabine IV SC day 2-5 9-12 absence disease progression unacceptable toxicity . MAINTENANCE : Following DELAYED INTENSIFICATION PART II , patient receive mercaptopurine PO NG day 1-168 , methotrexate IT day 1 92 PO weekly day 8-91 98-168 , hydrocortisone sodium succinate IT day 1 , 57 , 99 , cytarabine IT day 57 . Starting day 169 , patient receive mercaptopurine PO NG day 1-84 methotrexate PO weekly . Courses repeat every 84 day 2 year start INDUCTION CHEMOTHERAPY absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Cortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Cortisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>2-Aminopurine</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Patients must newly diagnose B lymphoblastic leukemia ( 2008 World Health Organization [ WHO ] classification ) ( also term Bprecursor acute lymphoblastic leukemia ) acute leukemia ambiguous lineage ; patient mixed phenotype acute leukemia eligible , provided morphology immunophenotype least 50 % B lymphoblastic Central nervous system ( CNS ) status must determine base sample obtain prior administration systemic intrathecal chemotherapy , exception steroid pretreatment Patients know MLL germline ( MLLG ) leukemia prior enrollment Patients Down syndrome Patients secondary B acute lymphoblastic leukemia ( BALL ) develop treatment prior malignancy cytotoxic chemotherapy With exception steroid pretreatment administration intrathecal methotrexate per protocol dosing , receipt prior cytotoxic chemotherapy either current diagnosis BALL cancer diagnose prior initiation protocol therapy AALL15P1</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>364 Days</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>